Physician profile
Eric Golderman
NPI 1639784523
$3,453.47
in general payments reported to CMS, 2019-2025
30 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,686 · 2022: $60.03 · 2023: $311 · 2024: $908 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $875.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $559.91 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $341.81 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $304.20 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $178.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $161.58 | 2021 | |
| Esperion Therapeutics, INC. | $124.76 | 2021 | |
| Pfizer INC. | $117.02 | 2021-2025 | |
| Amgen INC. | $76.31 | 2021-2024 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.62 | 2025 | Xifaxan |
| Astellas Pharma US INC | $56.35 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $55.51 | 2021-2024 | Capvaxive, Vaqta, Gardasil 9 |
| Currax Pharmaceuticals LLC | $55.30 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $51.79 | 2024 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $41.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $37.20 | 2021 | |
| Exact Sciences Corporation | $35.35 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $28.89 | 2024-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $27.08 | 2021 | |
| Nestle Healthcare Nutrition INC. | $25.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.87 | 2021 | |
| Amneal Pharmaceuticals LLC | $21.72 | 2021 | |
| Rgh Enterprises LLC | $21.04 | 2024 | |
| Tactile Systems Technology INC | $20.19 | 2024 | Entre Plus, Flexitouch Plus |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.89 | 2022 | |
| Sanofi Pasteur INC. | $18.83 | 2021 | |
| Renalytix Ai, INC. | $14.46 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Biogen, INC. | $13.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Golderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.